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A number of years ago, when the antihistamines became available it was
thought by many that substances had been found which, even if not panaceas,
at least would be effective against many allergic diseases.
At this time it must be stated that, even though these drugs have proven
helpful in some ways, they have also frequently caused eczematizations. Particu-
larly their topical use, such as in a cream or ointment, has led to many difficulties.
While in other countries eczemas caused by Pyribenzamine, Antistine and other
drugs have been reported since 1947 (1—6), Phenergan cream has been the main
cause in France. As a matter of fact the first sensitizations to Phenergan were
seen so soon after its appearance on the market as a cream that we have avoided
prescribing this remedy from the start.
In France many physicians and pharmacists appear to consider Phenergan
cream a suitable treatment for minor skin irritations and a specific treatment for
urticarias, eczemas and sunburn. It is obviously necessary that the side-effects
of this form of treatment should be known to all those who prescribe it. On vari-
ous occasions one of us has already called attention to some of these undesirable
side-effects (7—10). The present paper gives us an opportunity to review these
and to present our more complete data.
In the course of the last three years we have had reason to suspect Phenergan
as a causal or contributory factor in 262 cases of eczema. In 128 patients this
hypothesis has been confirmed and the skin tests were positive.
The importance of this number becomes evident from the fact that, according
to our statistics, it represents 50% of our cases of eruptions due to topical
medicaments and 15% of all our cases of eczema produced by external causes.
Often Phenergan cream brings about transformation of a mild eruption into
an acute dermatitis which is especially difficult to cure because the patient him-
self, temporarily relieved by the local anesthetic effects, often is difficult to
convince of the harmful action of the Phenergan cream and does not want to
stop it.
During the first days after sensitization to Phenergan cream, the eruption
manifests itself as acute eczema. The appearance and evolution depend on the
subject and on the type of lesion to which it has been applied: acute oozing and
vesicular eczemas, severe edematous and erythematous dermatitis, wet and
bright red scaly plaques, with outlying patches, and papulo-vesicular patches of
eczema are seen. As the eruption continues, all these different clinical types tend
to take on a more uniform appearance characterized by involvement of the
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exposed areas, i.e. the neck, face and forearms. These localizations are a sign
that photosensitization has occurred. They are reminiscent of what others as
well as we saw some years ago after the application of sulfonamides. Later on
in this report we shall discuss the stubborn character of photosensitization
dermatitis due to Phenergan.
CUTANEOUS ALLERGIC SENSITIZATION TO PHENEEGAN—REACTIONS TO ORALLY
ADMINISTERED PHENERGAN
The antipruritic and hypnotic properties of orally administered Phenergan
are at present utilized by many practitioners in the treatment of acute eczemas.
As far as we are concerned we are unwilling to run the risks involved in this treat-
ment. The majority of patients whom we see have eczemas in which a great
number of topical medicaments, more or less well tolerated, have already been
tried. Among them are many patients who are not conscious of having been
treated with Phenergan cream, and who will develop a reaction after internal
administration of this compound. It is impossible to predict beforehand the
extent and severity of these reactions. Usually there is a single rise in tempera-
ture 4—5 hours after ingestion of the tablet followed by reactivation of the erup-
tion the next day. Moreover, there may be extension of the eczema with de-
velopment of an erythroderma as well as systemic manifestations such as fever,
chills, intestinal upsets and sometimes even syncope.
The severity of these reactions is not necessarily dependent on the dose of
Phenergan and the length of time during which it is taken. In some subjects
we have seen local reactivations after absorption of Phenergan in homeopathic
dilution (11).
On the other hand a nurse, who had become sensitized by contact with in-
jectable Phenergan and who had taken 2 tablets of Phenergan every evening
against her itching and insomnia, developed during the first few days an intense,
edematous dermatitis of the face and arms. During the subsequent days the
eruption first remamed stationary and then regressed to some extent despite
continued ingestion of the same dose of Phenergan. In other patients such
treatment might well have provoked a progressive generalization and an eryth-
roderma.
It is obvious that it is important that one knows to which products these
patients have become sensitized in order to institute proper management and
to avoid the risks of reactions and recurrences entailed in exposing them to
Phenergan cream, tablets, syrup or injections.
SKIN TESTS—THE ROLE OF THE VEHICLE IN SENSITIZATIONS
TO PHENERGAN CREAM
The skin tests were carried out by the standard patch test technic and were
read after 48 hours. The systematic performance of these tests was helpful in
establishing in our patients the respective role which Phenergan and the cream
vehicle played in the genesis of their sensitizations.
In 83 of our patients in whom the clinical data suggested intolerance to Phen-
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TABLE 1
Tests in 83 subjects for sensitizing capacity of phenergan cream and phenergan solution
Number of Patirots Rrartioos to PbeoergaoCream Reactioos to Pbroergao
Reartioos to tbe Cream
Vebicle
27 + 0 +
11 + 0 0
5 0 0 +
5 + + +
1 0 + +
2 0
2 + + 0
1 0 + 0
ergan, tests were carried out with the commercially available Phenergau cream,
aqueous Phenergan solution and with the cream vehicle alone (Table 1). A sur-
prising number of reactions were produced by the vehicle alone. These almost
always sharply defined reactions varied from a simple erythema with slight
edema to a sharply defined intense erythema with a peculiar dryness and irrita-
tion of the skin. In the severe cases of dermatitis the reactions showed edema
and vesiculation accompanied by pruritus. The vehicle itself was irritating to
the skin and at times eezematogenic. In the 27 patients who reacted to Phenergan
cream and to the vehicle alone (but not to Phenergan solution) one could ask
oneself whether the reaction was caused by irritation or sensitization due to the
vehicle rather than by sensitization to Phenergan. In these cases the ingestion
test has helped us to solve the problem. The reactions which we have observed
after giving one tablet of Phenergan by mouth have shown us clearly that there
was in addition, or perhaps as a basic cause, a sensitization to Phenergan itself.
In the 11 subjects who reacted to the Phenergan cream but not to Phenergan
solution and to the cream vehicle alone one can think that the reaction was due
to a combination of the irritant or penetrating properties of the vehicle and the
sensitizing capacity of the drug itself. It is logical that the Phenergan solution
without the penetrating power of the cream vehicle would be tolerated by a
healthy skin whose defenses are unimpaired.
To restate the important points:
1) The vehicle of the commercial Phenergan cream has drying and irritating
properties which have produced slight to strongly positive reaction in 40 of 83
patients.
2) It is obvious that the association of that cream with a compound with
strong sensitizing properties such as Phenergan might bring about a particularly
dangerous synergism.
3) The relatively small number of reactions to Phenergan solution points up
the importance of the vehicle as a preparative factor. It explains why, at a time
when we used Phenergan in solution with Subtosan, * as suggested by Bensaude
* Subtosan is a 3.5% solution of polyvinvipyrrolidine isotonic and isoviscous to blood.
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for the treatment of anal pruritus, we observed an insignificant number of
sensitizations.
PHOTOSENSITIZATIONS TO PHENERGAN
Sensitizations to Phenergan cream are important because of their frequency,
the extent of the eruptions and the recurrences which occur after ingestion of
Phenergan syrup or tablets. They are negligible, however, in comparison to the
photosensitizations caused by this drug. The frequency and persistence and the
great difficulties which the photosensitizations cause in these patients have
already been described by one of us (20).
In the usual cases of sensitizations to a medicament, a cosmetic product, a
chemical agent, the patient can, if he knows the causal agent, remove or avoid
it and can carry on a normal life. The patient who is allergic to Phenergan
becomes, in the large majority of cases intolerant to sunlight as well as to regular
daylight! It is obvious that there are few reaction-causing agents which are more
difficult to avoid and in order to cure these patients we are forced to hospitalize
them in a dark room at times for as long as several weeks. We take great pre-
cautions before we let them return to a normal life and even then only after
having ascertained which is the best tolerated topical sunfiltering preparation
for their particular case. Moreover, we warn them that the photosensitization
can persist for several years.
In most cases the photosensitization presents a very suggestive appearance.
After the first few days the vesicular eczema disappears and is replaced by a
chronic, erythematous, dusky or carmine-colored dermatitis which is accom-
panied by dryness, fissuring and slight scaling. The existence of a photosensitiza-
tion can be recognized by the selective involvement of the face and hands with
borders at the neck, decolleté and sleeves. In some instances the reactions pro-
duced by light consisted not only of simple eczema of the exposed regions but
also other peculiar features which merit further study. Eruptions which had
been caused by topical and oral administration of Phenergan changed under the
influence of light into eruptions which resembled more light hypersensitivity
lesions than eczema. Here we have seen conditions resembling pellagra where the
skin was dusky red, thinned, atrophic, and tight with an ectropion of the eyelids
so much so tbat the face looked mummified. In two cases this was so striking
that we did porphyrin studies which, however, revealed normal values. The cure
of these eruptions presents much difficulty. One of our cases took three weeks
in total darkness to clear. Similarly we had the opportunity to treat and follow
patients in whom the Phenergan dermatitis disappeared only to make room for a
typical lupus erythematosus.
It is absolutely essential that physicians be aware of the frequency with which
Phenergan cream leads to light hypersensitivity, especially because of its serious
clinical features and its protracted course.
PHENERGAN INTOLERANCE AND cROSS-sENSITIzATIoN
Experiences with sensitizations to the group of compounds containing an
amino group in the para position have shown how the intolerance to a simple
TABLE 2
*s S
N '
PHENOTHIAZINE
The broken line shows where reduction could produce a primary amine
Antihistamines with a thiazine nucleus (1)
S S S
N N N
- + r1/ I /
I CH2—CH--N I C112-CH-N—0113 — CH3—CH2-dH3-N
I I \ so4
CH CH/C1H' 0113 CH \ CH3/C1HI CH
Phenergan Multergan Largactil
Other antihistamines (2)
COOH
HOH
I CHOH
- I
I CH 00011/
0113—CH2—N
0113
Pyribenzamine Thephorin
Para amino compounds
NH3 NH2
02115/
NH3 COO'C112_CH2—N
02115
Paraphenylenediamine Procaine (3)
(1.) All these compounds contain a tertiary amine (broken line). Multergan is a quater.
nary ammonium salt, closely related to the tertiary amines.
(2.) Only Pyribenzamine contains a tertiary amine in its molecule.
(3.) Procaine, like other local anesthetics, contains a tertiary amine.
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chemical can have far reaching consequences and can lead to reactions caused
by chemically related substances. It was logical to ask whether Phenergan would
also produce cross-sensitizations, a problem which has already been studied
by one of us (10).
A. Phenergan and the other antihistamines
Clinical experience has proven that allergic sensitization to Phenergan was
often associated with sensitization to Multergan hut only rarely to Thephorin
and Pyribenzamine. The similarity of the structure of Phenergan and Multergan
is evident (Table 2). In effect these two are related because they are both de-
rivatives of the group of thiazines. Thephorin and Pyribenzamine, two com-
pounds which appear to be usually well tolerated by patients who are allergic
to Phenergan, belong to different groups of compounds. This does not mean
that Thephorin and Pyribenzamine are not themselves capable of engendering
allergic sensitization. We have seen such cases and in Switzerland and in the
USA these two compounds appear to be frequent causes of dermatitis.
B. Phenergan and compounds containing a para-amino group
Of 128 Phenergan-intolerant patients 39, i.e. 30.7 % reacted also to p-phe-
nylenediamine. Some of them also had a sensitivity to the local anesthetics of
the novocaine series and to sulfonamides. This proportion is much too great to
be explainable by a simple coincidence.
One of us has already reported in 1952 that the reverse phenomenon was not
seen: subjects sensitized to p-phenylenediamine as a rule do not react to Phen-
ergan. Why then do Phenergan-sensitive patients often become intolerant to
p-phenylenediamine? The cross-sensitizations studied to date involved always
series of products of which the chemical parent substance was evident from the
examination of their breakdown products. A priori there is no chemical rela-
tionship which would explain a cross-sensitization between Phenergan and
compounds containing a p-amino group. In order to do this one would have to
admit that Phenergan is converted into a compound related to p-phenyiene-
diamine or into one of its breakdown products. From a chemical viewpoint one
can think of oxidative or reductive splitting mechanisms leading to primary
amines. One must recognize, however, that despite the uncertainty which still
surrounds many phenomena of chemical degradation in the organism or at the
skin surface, that there is little likelihood of their occurrence in vivo.
Even if one could admit that Phenergan could be transformed into substances
close to p-phenylenediamine and related compounds, it is absolutely certain
that p-phenylenediamine cannot be transformed into substances even distantly
related to Phenergan.
C. Phenergan and Largactil*
Largactil, a new ganglioplegic agent which is much used in psychiatry and
dermatology, has shown itself to be sometimes harmful in subjects sensitized
* In the United States of America Largactil is called Chiorpromazine hydrochloride; in
Germany: Meganhen; in Argentina: Ampliactil; in Brazil: Amplictil; in Sweden: Hibernal.
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to Phenergan. This phenomenon is easily understandable because of the great
chemical similarity of the two compounds (Table 2). In the beginning we used
this compound in all our eczema patients. We noted then that in some of them
the eruptions were aggravated, especially when they had had an eczema due to
Phenergan or to a member of the p-phenylenediamine group of compounds.
Among U Phenergan-sensitive patients, whom we tested with Largactil,
positive reactions were seen in three. In two, a reactivation of the eruption
occurred after taking one Largactil tablet. One of these reactions was frightening
because of its intensity and the general phenomena with which it was associated.
This was a nurse whose case we have reported with our teacher, Dr. Tzanck,
before the Société Francaise de Dermatologie. This subject had become sensi-
tized to Phenergan and Largactil which she had handled daily in the form of the
injectable solution. Her eruption was practically entirely cleared when 12 hours
after taking a Largactil tablet she developed severe edema of the hands, arms
and face as well as vertigo and tendency to fainting. This reaction subsided
slowly over a 15 day period.
Largactil itself apparently has a considerable sensitizing capacity. We have
seen such sensitizations repeatedly in workers engaged in its manufacture and,
as stated above, in nurses handling it in inj ectable form. Pellerat (12) in Lyon
has already called attention to the frequent occurrence of eczemas among the
nurses handling this compound in a psychiatric center.
Even if Largactil renders great services, it should under no circumstances
ever be used topically. Recently such use has been suggested but it can be ex-
pected that it would cause even much stronger sensitizations than those which
have already been caused by Phenergan (12, 13).
One should be aware of the fact that study of the chemistry of Phenergan,
Largactil, Pyribenzamine and certain local anesthetics reveals that they have
in common a tertiary aliphatic amine which certain authors (14) have considered
a determining factor in sensitization to Novocaine. Finally we want to recall the
fact that certain cosmetologists wanted to incorporate antihistamines in cos-
metic preparations in order to avoid intolerance reactions. One can imagine
how many sensitization and photo sensitization reactions this type of product
could produce.
SUMMARY AND CONCLUSIONS
One-half of all eczemas of therapeutic origin seen by us in 1953 were due to
Phenergan cream. This leads us to no longer prescribe Phenergan internally
because we are always afraid that at some previous time the patient may have
applied this medicament locally against a dermatitis or itching. The stubborn
photosensitizations which follow Phenergan intolerance represent a severe
handicap to the patients. The incorporation of Phenergan in a cream actually
produces the maximum chances for sensitization. It would have been preferable
to use it in solution like in a calamine lotion. In our hands this type of Phenergan
preparation has shown itself to be much less reaction-producing.
It is of equally great importance for the physician and his patients to know
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the relationships between the different synthetic drugs and the consequences
which may occur because of these relationships. We advise our patients who have
become sensitized in this way to avoid the application of antihistamine oint-
ments (especially of Phenergan cream), the oral or parenteral administration of
certain antihistamine drugs (Phenergan, Largactil, Multergan); and we also
call attention to the possibility of sensitization to other substances (local anes-
thetics of the novocaine series, hair dyes, sulfonamides).
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